| Liu, Tianshu |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
COMPASSIOn-15, NCT05008783: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma |
|
|
| Active, not recruiting | 3 | 610 | RoW | AK104, Oxaliplatin, Capecitabine, Placebo | Akeso | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 08/24 | 04/25 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
|
| Completed | 2 | 50 | RoW | GS+Toripalimab | Shanghai Zhongshan Hospital, Shanghai Junshi Bioscience Co., Ltd., OrigiMed | Biliary Tract Cancer | 12/21 | 03/22 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations |
|
|
| Recruiting | 2 | 200 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
| Recruiting | 2 | 156 | RoW | SHR-A1811；SHR-1701；capecitabine；oxaliplatin | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | 07/26 | 07/26 | | |
NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN |
|
|
| Recruiting | 2 | 60 | RoW | PM8002, FOLFIRI | Biotheus Inc. | Neuroendocrine Neoplasm | 01/27 | 01/28 | | |
NCT05357196: PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | PT-112, Gemcitabine | SciClone Pharmaceuticals | Biliary Tract Cancer | 08/22 | 04/23 | | |
| Recruiting | 1/2 | 222 | RoW | SHR-1701, Famitinib | Jiangsu HengRui Medicine Co., Ltd. | Solid Tumor | 12/22 | 10/23 | | |
NCT05008445: Study of LM-102 in Patients With Advance Solid Tumors |
|
|
| Terminated | 1/2 | 11 | RoW | LM-102 Injection, LM-102 Injection combined with SOC | LaNova Medicines Development Co., Ltd., Shanghai Zhongshan Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Zhejiang University, Sir Run Run Shaw Hospital | Advanced Solid Tumor | 02/23 | 02/23 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT04612712: A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors |
|
|
| Recruiting | 1/2 | 42 | RoW | Donafenib Tosilate Tablets, KN046 Injection | Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Gastrointestinal Tumors | 12/23 | 12/23 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT05205850: A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors |
|
|
| Recruiting | 1/2 | 135 | RoW | RC118-ADC, RC118 for injection | RemeGen Co., Ltd. | Advanced Solid Tumor | 09/25 | 12/25 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT06111326: BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 1/2 | 83 | RoW | BC3402 injection, Durvalumab injection | Biocity Biopharmaceutics Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 05/26 | | |
NCT05383482: Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 |
|
|
| Active, not recruiting | 1/2 | 22 | RoW | Afuresertib, LAE002, Nab paclitaxel, Docetaxel, Sintilimab | Laekna Limited | Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric and Gastroesophageal Junction Adenocarcinoma | 06/24 | 12/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT05906524: KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 85 | RoW | KD6001, Tislelizumab, Bevacizumab | Shanghai Kanda Biotechnology Co., Ltd. | Advanced HCC, Other Solid Tumors | 04/25 | 12/25 | | |
NCT06038396: A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 48 | RoW | RC118, RC118 for injection, Toripalimab, Toripalimab injection, JS001, RC148 | RemeGen Co., Ltd. | Advanced Solid Tumor | 02/26 | 08/26 | | |
| Recruiting | 1b | 38 | RoW | ZN-c3, Study Drug | Zentera Therapeutics HK Limited | Solid Tumors | 06/22 | 06/23 | | |
NCT04689100: Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 259 | RoW | JMT101, FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);, FOLFIRI; mFOLFOX6; Irinotecan; | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumor | 12/21 | 06/22 | | |
NCT04381325: A Study of MSB0254 Injection in Advanced Solid Tumors |
|
|
| Terminated | 1 | 25 | RoW | MSB0254 Injection | Suzhou Transcenta Therapeutics Co., Ltd. | Advanced Solid Tumor | 06/22 | 06/22 | | |
NCT05173792: Study of AK119 in Subjects With Advanced Solid Tumors |
|
|
| Completed | 1 | 16 | RoW | AK119 | Akeso | Solid Tumor | 05/23 | 05/23 | | |
BL0006-101, NCT06247657: A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1 | 66 | RoW | BL0006 | Shanghai Best-Link Bioscience, LLC | Advanced Solid Tumor | 10/24 | 05/25 | | |
NCT06225622: Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer |
|
|
| Recruiting | 1 | 78 | RoW | Irinotecan Liposome, Oxaliplatin, 5-FU, LV, Bevacizumab, Cetuximab | Shanghai Zhongshan Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Metastatic Colorectal Cancer | 01/26 | 05/26 | | |
NCT05369312: Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients |
|
|
| Not yet recruiting | 1 | 230 | RoW | BPI-442096 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer | 05/24 | 05/25 | | |
NCT05193721: A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors |
|
|
| Active, not recruiting | 1 | 25 | RoW | SHR-1901 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Malignant Tumors | 06/24 | 08/24 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
NCT05886374: A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 81 | RoW | HMPL-415S1 | Hutchmed | Advanced Malignant Solid Tumors | 05/25 | 06/26 | | |
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors |
|
|
| Terminated | 1 | 20 | RoW | ABM-1310 | ABM Therapeutics Shanghai Company Limited | Advanced Solid Tumor, BRAF V600 Mutation | 06/24 | 06/24 | | |
| Not yet recruiting | 1 | 410 | RoW | NBL-015 | NovaRock Biotherapeutics, Ltd | Advanced Solid Tumors | 12/25 | 12/25 | | |
